[Federal Register: June 24, 2003 (Volume 68, Number 121)]
[Notices]
[Page 37503-37504]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jn03-78]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Antiviral Drugs Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Antiviral Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on August 20, 2003, from 8
a.m. to 5 p.m.
Location: Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave.,
Bethesda, MD.
Contact Person: Tara P. Turner, Center for Drug Evaluation and
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857,
(301)827-7001, e-mail: TurnerT@cder.fda.gov, or FDA Advisory Committee
Information Line, 1-800-741-8138 ((301)443-0572 in the Washington, DC
area), code 12531. Please call the Information Line for up-to-date
information on this meeting.
Agenda: The committee will discuss clinical trial design issues in
the development of topical microbicides for the reduction of HIV
transmission.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by August 13,
2003. Oral presentations from the public will be
[[Page 37504]]
scheduled between approximately 1 p.m. and 2 p.m. Time allotted for
each presentation may be limited.
Those desiring to make formal oral presentations should notify the
contact person before August 13, 2003, and submit a brief statement of
the general nature of the evidence or arguments they wish to present,
the names and addresses of proposed participants, and an indication of
the approximate time requested to make their presentation. Persons
attending FDA's advisory committee meetings are advised that the agency
is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Tara Turner at least
7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: June 13, 2003.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 03-15890 Filed 6-23-03; 8:45 am]
BILLING CODE 4160-01-S